TY - JOUR T1 - Life course longitudinal growth and risk of knee osteoarthritis at age 53 years: evidence from the 1946 British birth cohort study JF - medRxiv DO - 10.1101/2020.08.18.20177485 SP - 2020.08.18.20177485 AU - Katherine A. Staines AU - Rebecca Hardy AU - Hasmik J. Samvelyan AU - Kate A. Ward AU - Rachel Cooper Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/21/2020.08.18.20177485.abstract N2 - Objectives To examine the relationship between height gain across childhood and adolescence with knee osteoarthritis in the MRC National Survey of Health and Development (NSHD).Methods Data are from 3035 male and female participants of the NSHD. Height was measured at ages 2, 4, 6, 7, 11 and 15 years, and self-reported at ages 20 and 26 years. Associations between (i) height at each age (ii) height gain during specific life periods (iii) Super-Imposition by Translation And Rotation (SITAR) growth curve variables of height size, tempo and velocity, and knee osteoarthritis at 53 years were tested.Results In sex-adjusted models, taller height at 4 and 6 years were modestly associated with decreased odds of knee osteoarthritis at age 53 (ORs per 1cm increase in height at age 6: 0.97 and age 4: 0.98 (95% CI: 0.95-1.00)). These associations were attenuated after adjustment for potential confounders. Similarly, taller adult achieved height measured at 26 and 53 years of age were associated with decreased odds of knee osteoarthritis (OR per 1cm increase in height: 0.98 (95% CI 0.96 to 1.00)). No associations were found between height gain during specific life periods or the SITAR growth curve variables and odds of knee osteoarthritis.Conclusions There was some limited evidence to suggest that taller height in childhood is associated with decreased odds of knee osteoarthritis at age 53 years in this cohort. This work enhances our understanding of osteoarthritis predisposition and the contribution of life course height to this.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors would like to acknowledge the Medical Research Council for funding to KS (MR/R022240/1).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The data collection at age 53 years received ethical approval from the North Thames Multi-centre Research Ethics Committee, and written informed consent was given by all respondents.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in this publication are available to bona fide researchers upon request to the NSHD Data Sharing Committee via a standard application procedure. Further details can be found at http://www.nshd.mrc.ac.uk/data. doi: 10.5522/NSHD/Q101 ER -